000520 — Samil Pharmaceutical Co Share Price
Last trade - 00:00- KR₩170bn
- KR₩323bn
- KR₩196bn
- 15
- 55
- 14
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.09 | ||
| Price to Tang. Book | 1.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.83 | ||
| EV to EBITDA | 28.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.48% | ||
| Return on Equity | -0.55% | ||
| Operating Margin | 3.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 121,107.09 | 122,998.99 | 134,246.78 | 179,676.11 | 196,345.81 | n/a | n/a | 15.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +74.68 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Company’s products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
Directors
- Gang Huh CHM (60)
- V.S. Ram PRE (62)
- Seung Beom Huh CCE (32)
- Bu Hwan Goh VPR (57)
- Jong Pyo Hong OTH (52)
- Gi Dong Kim OTH (60)
- Jin Suk Kim OTH (47)
- Tae Gyeong Kim OTH (49)
- Gyeong Cheol Oh OTH (49)
- Gi Jeong Lee DRC (83)
- Jong Nam Kim NID (58)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 7th, 1947
- Public Since
- May 29th, 1985
- No. of Shareholders
- 9,937
- No. of Employees
- 395
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 20,107,559
- Address
- Samil Pharmaceutical Office Bldg., SEOUL, 06666
- Web
- http://www.samil-pharm.com/
- Phone
- +82 25200300
- Auditors
- Ernst & Young Han Young
Upcoming Events for 000520
Similar to 000520
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 23:03 UTC, shares in Samil Pharmaceutical Co are trading at KR₩8,480. This share price information is delayed by 15 minutes.
Shares in Samil Pharmaceutical Co last closed at KR₩8,480 and the price had moved by +13.22% over the past 365 days. In terms of relative price strength the Samil Pharmaceutical Co share price has outperformed the FTSE Developed Asia Pacific Index by +8.34% over the past year.
There is no consensus recommendation for this security.
Samil Pharmaceutical Co does not currently pay a dividend.
Samil Pharmaceutical Co does not currently pay a dividend.
Samil Pharmaceutical Co does not currently pay a dividend.
To buy shares in Samil Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩8,480, shares in Samil Pharmaceutical Co had a market capitalisation of KR₩171bn.
Here are the trading details for Samil Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 000520
Based on an overall assessment of its quality, value and momentum Samil Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Samil Pharmaceutical Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +30.37%.
As of the last closing price of KR₩8,480, shares in Samil Pharmaceutical Co were trading +5.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Samil Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩8,480.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Samil Pharmaceutical Co's management team is headed by:
- Gang Huh - CHM
- V.S. Ram - PRE
- Seung Beom Huh - CCE
- Bu Hwan Goh - VPR
- Jong Pyo Hong - OTH
- Gi Dong Kim - OTH
- Jin Suk Kim - OTH
- Tae Gyeong Kim - OTH
- Gyeong Cheol Oh - OTH
- Gi Jeong Lee - DRC
- Jong Nam Kim - NID